when were glp 1 agonists discovered The expanding landscape of GLP-1 medicines The transformative breakthroughs in GLP-1
Description
M., Capella, C., Solcia, E
Diabetes Metab J 44(6):80218 Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS et al (2022) LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept
10.1016/j.kint.2022.10.030 [DOI] [PubMed] [Google Scholar] 87
Bioorg Med Chem
As a dual agonist, it targets both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: The T-emerge 2 trial
